Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
210.10 x 2,700 210.50 x 300
Post-market by (Cboe BZX)
210.01 -1.95 (-0.92%) 03/21/25 [NYSE]
210.10 x 2,700 210.50 x 300
Post-market 210.01 unch (unch) 19:33 ET
Quote Overview for Fri, Mar 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
208.74
Day High
212.88
Open 211.73
Previous Close 211.96 211.96
Volume 16,657,700 16,657,700
Avg Vol 6,957,895 6,957,895
Stochastic %K 44.59% 44.59%
Weighted Alpha +22.91 +22.91
5-Day Change -1.76 (-0.83%) -1.76 (-0.83%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 374,184,640
  • Shares Outstanding, K 1,765,355
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.61
  • Price/Sales 6.65
  • Price/Cash Flow 14.21
  • Price/Book 111.50

Options Overview Details

View History
  • Implied Volatility 22.70% ( +0.79%)
  • Historical Volatility 16.03%
  • IV Percentile 62%
  • IV Rank 45.32%
  • IV High 30.36% on 10/29/24
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 0.69
  • Today's Volume 29,300
  • Volume Avg (30-Day) 20,391
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 398,387
  • Open Int (30-Day) 355,362

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.51
  • Number of Estimates 9
  • High Estimate 2.61
  • Low Estimate 2.48
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +8.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.28 +4.34%
on 02/24/25
Period Open: 202.08
218.66 -3.96%
on 03/10/25
+7.93 (+3.92%)
since 02/21/25
3-Month
168.06 +24.96%
on 01/22/25
Period Open: 175.58
218.66 -3.96%
on 03/10/25
+34.43 (+19.61%)
since 12/20/24
52-Week
153.58 +36.74%
on 05/30/24
Period Open: 177.50
218.66 -3.96%
on 03/10/25
+32.51 (+18.32%)
since 03/21/24

Most Recent Stories

More News
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 163.63 (+0.37%)
MRK : 93.11 (-1.71%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy? The...

ABBV : 210.01 (-0.92%)
3 Dividend Stocks to Buy for Reliable Passive Income

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037,...

CVX : 164.75 (-0.01%)
ABBV : 210.01 (-0.92%)
PFE : 26.28 (+0.34%)
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...

NVO : 76.86 (-2.45%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
AMGN : 316.04 (+0.32%)
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction

Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the opposite direction of stock prices. So, with the stock market recently correcting...

SCHW : 78.39 (-0.23%)
SCHD : 27.76 (-0.68%)
ABBV : 210.01 (-0.92%)
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025

Investors typically turn to dividend-paying stocks and exchange-traded funds (ETFs) to boost their passive income streams so that their returns aren't solely tied to stock price gains. But so far this...

GOOGL : 163.99 (+0.73%)
AAPL : 218.27 (+1.95%)
AVGO : 191.66 (+0.59%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
BRK.TO : 39.08 (-1.34%)
UNH : 516.85 (+1.09%)
COMP : 9.39 (+3.30%)
MSFT : 391.26 (+1.14%)
TSLA : 248.71 (+5.27%)
V : 335.66 (-1.13%)
LLY : 837.57 (-0.59%)
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The demand for healthcare products and services typically holds up very well regardless...

KNSA : 23.36 (-1.89%)
VRTX : 503.20 (-1.37%)
AGN.AX : 0.860 (+7.50%)
ABBV : 210.01 (-0.92%)
Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.

VICI : 31.53 (-1.50%)
NVDA : 117.70 (-0.70%)
ABBV : 210.01 (-0.92%)
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?

Vanguard has some excellent dividend ETFs, but they are right for different investors.

AAPL : 218.27 (+1.95%)
AVGO : 191.66 (+0.59%)
BAC : 42.47 (-0.02%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
VYM : 128.40 (-0.42%)
ABBV : 210.01 (-0.92%)
UNH : 516.85 (+1.09%)
MSFT : 391.26 (+1.14%)
COST : 909.26 (+1.55%)
MA : 535.69 (-0.13%)
VIG : 194.17 (-0.17%)
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

MYGN : 10.01 (+1.01%)
BMRN : 71.24 (-0.50%)
GILD : 107.08 (+1.14%)
ABBV : 210.01 (-0.92%)
MRNA : 32.66 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 216.49
2nd Resistance Point 214.68
1st Resistance Point 212.35
Last Price 210.01
1st Support Level 208.21
2nd Support Level 206.40
3rd Support Level 204.07

See More

52-Week High 218.66
Last Price 210.01
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Fibonacci 38.2% 178.44
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals